HISTORY Building a Better Tomorrow, Every Day Every day we are innovating and evolving into new areas where there is great unmet need and opportunity to help people living with rare diseases and their families fully live their best lives. 2020 ACQUISITION Acquired Portola Pharmaceuticals, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders ACQUISITION Acquired Achillion Pharmaceuticals, the company that began development of two oral factor D inhibitors 2019 APPROVAL Treatment approved for adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) ABOUT aHUS APPROVAL First complement inhibitor approved for adult patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) ABOUT NMOSD CHELSEY LIVING WITH NMOSD PARTNERSHIP Established partnerships with Caelum Biosciences, Zealand Pharma, and Affibody 2018 APPROVAL Treatment approved for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) ABOUT PNH VICTOR LIVING WITH PNH PARTNERSHIP Established partnerships with Complement Pharma and Dicerna PIPELINE ACQUISITION Acquired Syntimmune, the company that began development of a treatment for rare IgG-mediated diseases ACQUISITION Acquired Wilson Therapeutics, the company that began development of a treatment for Wilson Disease COMPANY MILESTONE Opened global headquarters in Boston 2017 PARTNERSHIP Partnered with Halozyme Therapeutics and established license agreement for ENHANZE® drug-delivery technology PIPELINE APPROVAL First complement inhibitor approved for adult patients with generalized Myasthenia Gravis (gMG) ABOUT gMG JESSE LIVING WITH gMG 2016 COMPANY MILESTONE Opened the Center of Excellence in New Haven 2015 APPROVAL First treatment approved for patients with lysosomal acid lipase deficiency (LAL-D) ABOUT LAL-D APPROVAL First treatment approved for patients with hypophosphatasia (HPP) ABOUT HPP EVIE LIVING WITH HPP ACQUISITION Acquired sebelipase alfa, a potential treatment for patients living with LAL-D 2012 ACQUISITION Acquired asfostase alfa, a potential treatment for patients living with HPP 2011 APPROVAL First treatment approved for patients with atypical hemolytic uremic syndrome (aHUS) ABOUT aHUS 2007 APPROVAL First treatment approved for patients with paroxysmal nocturnal hemoglobinuria (PNH) ABOUT PNH JOE LIVING WITH PNH 1996 COMPANY MILESTONE Alexion goes public with ticker ALXN 1992 COMPANY MILESTONE Alexion founded in New Haven, CT RELATED TOPICS Stay on top of what we do every day NEWS & MEDIA Help is out there and we’re not alone anymore.” JILL LIVING WITH aHUS HEAR HER STORY MEDICAL PROFESSIONALS THE RARE DISEASE COMMUNITY INVESTORS JOB SEEKERS Contact Us Legal Statement Privacy Notice Terms of Use Cookies Settings This website is intended only for residents of the United States. © 2021 Alexion Pharmaceuticals, Inc. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Reject All Cookies Accept All Cookies